HDAC9 and Miyoshi myopathy: Compared with sustained PI monotherapy, a combination therapy strategy using PIs and HDAC inhibitors or an increased dosage intermittent therapy can be more effective in treating MM by preventing the emergence of tolerant cancer cells.